Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment and Prognosis of Patients With Chronic HBV Infection
Sponsor: Xiangya Hospital of Central South University
Summary
Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.
Official title: Study on the Antiviral Therapy and Prognosis of Patients With Chronic HBV Infection
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2021-10-25
Completion Date
2026-10-25
Last Updated
2022-05-26
Healthy Volunteers
Yes
Conditions
Interventions
Standard antiviral therapy
pegylated interferon or/and nucleos(t)ide analogues
Locations (1)
Department of Infectious Disease, Xiangya Hospital, Central South University
Changsha, Hunan, China